A Randomized, Non-inferiority, Double-blind, Controlled, Single-dose, 2-way Cross-over Study to Assess the Potential for Airway Sensitivity Reactions With Propellants HFA-152a (Test) and HFA-134a (Reference) Administered Via Pressurized Metered Dose Inhalers in Adults Aged 18-45 With Mild Asthma

The purpose of the study is to assess the propellants,1 - Difluoroethane [HFA-152a] (Test) and 1,1,1,2-Tetrafluoroethane [HFA-134a] (Reference) for their potential to cause the airways to tighten when delivered through pressurized metered dose inhalers (pMDI). The rationale for this study is to develop a low carbon footprint alternative propellant, HFA-152a, which will have a lower impact on global warming.

开始日期2025-03-18

申办/合作机构

GSK Plc

NCT06433921

/ Recruiting临床1期

A Phase 1, Randomized, 2-part, 7-way Cross-over (Part 1) and 7-way Cross-over (Part 2), Active Device Blinded, Single Dose Study in Mild Asthmatics Aged 18-65 to Assess the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers Containing Propellants HFA-152a (Test) and HFA-134a (Reference) Via Methacholine Bronchoprovocation and Systemic Pharmacodynamic Effects

The primary objectives of the study are:
* Part 1: to characterize the potency and variability of dose response on efficacy (Provocative concentration of methacholine causing at least a 20% fall in forced expiratory volume (FEV1) [PC20]) of salbutamol administered via MDI with salbutamol HFA-134a or salbutamol HFA-152a in participants with mild asthma.
* Part 2: to compare the comparative dose response on efficacy (PC20) of salbutamol when administered via MDI with salbutamol HFA-134a or salbutamol HFA-152a in participants with mild asthma.

开始日期2024-08-14

申办/合作机构

GSK Plc

NCT06506266

/ Completed临床1期

A Randomized, Double-blind, Single-site, Two-way Crossover Phase 1 Study to Assess the Effect of Repeated Doses of Test Propellant (HFA-152a) on Mucociliary Clearance as Compared to Reference Propellant (HFA-134a) in Healthy Male and Female Participants

The main goal of the study is to assess the effect of the administration of reference propellant [HFA-134a (1,1,1,2 - Tetrafluoroethane)] and test propellant [HFA-152a (1 - Difluoroethane)] in healthy adults on mucociliary clearance (MCC).

开始日期2024-07-29

申办/合作机构

GSK Plc

100 项与 1,1-二氟乙烷相关的临床结果

登录后查看更多信息

100 项与 1,1-二氟乙烷相关的转化医学

登录后查看更多信息

100 项与 1,1-二氟乙烷相关的专利（医药）

登录后查看更多信息

项与 1,1-二氟乙烷相关的文献（医药）

2025-06-01·PULMONARY PHARMACOLOGY & THERAPEUTICS

Impact on beclometasone dipropionate pharmacokinetics when switching to a low global warming potential propellant in a pressurised metered-dose inhaler

Article

作者: Pacchetti, Ilaria ; Mathews, Kusum S ; Van Leuven, Katrin ; Martini, Matteo ; Rony, François ; Contursi, Cristina ; Poli, Gianluigi ; Viganò, Luca Vittorio ; Pittelli, Maria Gloria ; Calabrò, Emanuele Rocco

INTRODUCTION:

Use of high global warming potential propellants (e.g., HFA-134a) for pressurised metered-dose inhalers (pMDIs) is being phased down. Beclometasone dipropionate (BDP) is approved for the treatment of asthma in several countries via an HFA-134a propellant pMDI. This is being reformulated using the low global warming potential propellant HFA-152a. Two studies compared BDP pharmacokinetics delivered via pMDI using HFA-152a vs HFA-134a.

METHODS:

Both studies (N=71/study) were single-dose (four inhalations of BDP), randomised, double-blind, crossover (Study 1, four-way; Study 2, two-way), in healthy volunteers. In Study 1, subjects inhaled BDP via HFA-134a pMDI in two periods (200 μg/actuation in one period, 100 μg/actuation in the other) and HFA-152a pMDI in the other two (200 or 100 μg/actuation). In Study 2, subjects inhaled BDP 200 μg/actuation via HFA-134a or HFA-152a pMDI using a spacer device. pMDIs containing HFA-152a and HFA-134a were compared in terms of lung availability (BDP comparisons) and total systemic exposure (beclometasone-17-monopropionate comparisons [B17MP; active metabolite of BDP]), with bioequivalence concluded if the 90% confidence intervals (CIs) of the geometric mean ratios of maximum plasma concentration (C_max) and area under the plasma concentration-time curve between time zero and the last quantifiable timepoint (AUC_0-t) were between 80-125%.

RESULTS:

BDP C_max and AUC_0-t were equivalent for the two BDP 200 μg formulations, without (Study 1) and with spacer (Study 2). BDP 100 μg AUC_0-t met the bioequivalence criteria, but the C_max lower 90% CI was marginally below the bioequivalence limit (79.46%). B17MP C_max and AUC_0-t were bioequivalent with both propellants in all three comparisons.

CONCLUSIONS:

Overall, bioequivalence was confirmed of HFA-152a and HFA-134a for BDP 200 μg/actuation, with and without a spacer. Although bioequivalence of the two formulations cannot be formally concluded for BDP 100 μg, the minimal difference suggests the two formulations can be considered therapeutically equivalent.

2025-06-01·PULMONARY PHARMACOLOGY & THERAPEUTICS

The low global warming potential propellant HFA-152a does not induce bronchoconstriction or impair mucociliary clearance

Article

作者: Poli, Gianluigi ; Cortellini, Mauro ; Pacchetti, Ilaria ; Mathews, Kusum ; Foti, Martina ; Rony, François ; Emirova, Aida ; Singh, Dave ; Puviani, Veronica ; Girardello, Luca ; Salvadori, Michela

INTRODUCTION:

Use of propellants with high global warming potential (e.g., HFA-134a) for pressurised metered-dose inhalers is being phased down. An alternative is reformulation using propellants with low global warming potential (e.g., HFA-152a), which requires evaluation of the propellant's safety, in particular whether it induces bronchoconstriction or impairs mucociliary clearance (MCC). In this manuscript, we describe two studies, the first comparing the bronchoconstriction potential of HFA-152a vs HFA-134a, the second comparing their effect on MCC.

METHODS:

The bronchoconstriction study was single-dose, randomised, double-blind, controlled, crossover, in adults with asthma. The primary endpoint was relative change from baseline in forced expiratory volume in 1 s (FEV₁) at 15 min post-dose. The MCC study was multiple-dose (8 days), randomised, open-label, controlled, crossover, in healthy volunteers. The primary endpoint was percent particle retention in the right whole lung at 2 and 4 h after inhalation of radiolabelled particles (PPR₂ and PPR₄).

RESULTS:

For the bronchoconstriction study (N = 25), the 95 % CI of the adjusted mean FEV₁ difference between HFA-152a vs HFA-134a at 15 min post-dose was within the -10 % to +10 % equivalence limit (1.86 % [95 % CI -0.48 %, 4.20 %]; p = 0.113). Treatment-emergent adverse events were reported by 4.0 % (HFA-152a) and 12.0 % (HFA-134a) patients, all mild or moderate in intensity, and none serious. For the MCC study (N = 20), the 95 % CIs for the adjusted mean differences between HFA-152a vs HFA-134a at Day 8 contained 0 for both PPR₂ (1.36 [-2.28, 4.99]%; p = 0.442) and PPR₄ (0.70 [-1.73, 3.12]%; p = 0.553). A similar proportion of subjects had treatment-emergent adverse events (25.0 % vs 35.0 %), all mild in intensity, and none serious.

CONCLUSIONS:

These two studies suggest a switch in propellant from HFA-134a to HFA-152a is unlikely to induce post-dose bronchoconstriction in asthma or impact lung MCC, and is not accompanied by any safety concerns.

2025-02-01·Journal of Aerosol Medicine and Pulmonary Drug Delivery

Comparison of Formoterol, Glycopyrrolate, and Beclomethasone Dipropionate Pharmacokinetic Profile after Inhaled Administration as pMDI Using HFA134a or HFA152a Propellant: Preclinical Assessment of Drug Exposure in Sprague–Dawley Rat Model

Article

作者: Fioni, Alessandro ; Cuoghi, Erika ; Zambelli, Enrico ; Puccini, Paola ; Allen, Andrew Dennis ; Miglietta, Daniela ; Brogin, Giandomenico ; Battipaglia, Loredana

Background: A fixed combination of formoterol, glycopyrrolate, and beclomethasone dipropionate is approved in some geographic areas as pressurized metered dose inhaler (pMDI) formulation for the treatment of asthma and chronic obstructive pulmonary disease. Current pMDIs use hydrofluoroalkanes (HFAs) as a propellant, such as 1,1,1,2-tetrafluoroethane (HFA134a), that have a high global warming potential (GWP), but their use is being progressively lowered to reduce impact on climate. One option to reduce the carbon footprint of the pMDI products while preserving pMDIs as a therapeutic option is reformulating the current pMDIs using low GWP propellants, such as 1,1-difluoroethane (HFA152a). Nevertheless, pharmaceutical, clinical, and regulatory challenges need to be considered when reformulating a pMDI. A nonclinical study in rodents has been performed to support the formulation work and optimize the design of the bioequivalence study in humans. Methods: A fixed combination of formoterol, glycopyrrolate, and beclomethasone dipropionate (BDP) as pMDI with the two propellants HFA134a or HFA152a was administered by inhalation to Sprague-Dawley rats, using inhalation tower, to assess the impact of the propellant on the PK profile of the active components. After administration, serial blood samples were taken from each rat, and plasma aliquots were analyzed by HPLC-MS/MS. Results: Inhalation administration to rats of the fixed triple combination as pMDI showed similar PK profile for formoterol, glycopyrrolate, and BDP with the two propellants. Exposure parameters C_max and AUC_last of the three active ingredients were compared, showing no statistically significant differences in the systemic exposure between the two treatment groups. Higher interanimal variability was observed for the metabolite beclomethasone 17-monopropionate, likely due to individual differences in the metabolite generation. Conclusions: Considering these data, it was possible to conclude that replacing propellant HFA134a with HFA152a in a newly developed formulation had no significant impact on the plasmatic PK profile of formoterol, glycopyrrolate, and BDP in rats after inhalation administration using inhalation towers.

项与 1,1-二氟乙烷相关的新闻（医药）

2024-07-06

·医药地理

前沿领航 | 创新驱动下的现代吸入制剂技术、辅料与装置

7月5日，“吸入药物递送国际学术研讨会暨中国颗粒学会吸入颗粒专业委员会2024 年学术研讨会（第三届）”在辽宁沈阳顺利召开。作为本届大会的重要专题论坛之一，“现代吸入制剂技术与创新：新技术、新辅料、新装置前沿探索”于7月5日下午在大会开幕式当天同期举行。新药技术百花齐放，前沿知识层出不穷。得益于独特的临床优势，高端制剂的“技术与创新”正引领着一场革命，不仅能提升药品的治疗效果和安全性，也能为患者带来更好的用药体验。本场专题论坛深度聚焦吸入制剂领域的技术突破，包括创新药物递送系统、高效辅料的开发、智能吸入装置的设计、以及相关产业化，讨论如何通过前沿技术实现药物精准释放，以期提高疗效、减少不良反应。中国颗粒学会吸入颗粒专委会主任沈阳药科大学教授毛世瑞中国颗粒学会吸入颗粒专委会主任、沈阳药科大学教授毛世瑞以“基于粒子微结构的吸入组方设计基础”为主题作了精彩的开篇演讲。近些年，由于人口老龄化、空气污染等因素，肺部呼吸疾病的发病率非常高，针对肺部疾病，肺部递送给药具有一定的治疗优势，因此，微纳米技术在肺部吸入领域应用广泛。通过研究肺部组织递送屏障、肺表面活性剂组成、不同电性脂质体的制备表征、脂质体表面电性对黏液渗透及气管分布的影响、脂质体表面电性对肺表面活性剂层/肺泡巨噬细胞吞噬的影响、脂质体表面电性对肺部滞留/组织分布影响等，可以提高吸入药物的治疗效果，为改良新药奠定了研究基础。浙江知一药业董事长王兆霖浙江知一药业董事长王兆霖为与会嘉宾们带来了主题为“大分子干粉吸入及产业化”的报告。生物大分子是指各种分子量达到上万或更多的作为生物体内主要活性成分的有机分子，生物大分子药物多用于治疗肿瘤、艾滋病、心血管疾病、肝炎等重大疾病，用于哮喘和肺纤维化尚不是主流。与传统注射剂相比，大分子干粉吸入更便捷且避免交叉感染。随后，他以热敏吸入大分子粉末的制造和工业化难题为例，讲述了常压冷冻干燥技术的开拓和发展，以及新型喷雾冷冻干燥技术的应用，基于该技术，知一药业完成了环丙沙星脂质体干粉吸入剂、融合蛋白干粉吸入的开发。苏州大学教授吴铎苏州大学教授吴铎围绕“受蒲公英启发的吸入粉雾剂微粒结构设计与宏量制备技术”作了精彩分享。他表示，经口吸入粉雾剂由于不同的类型，在罐装、用药剂量和制作工艺方面有着不同的特点，AeDPI制剂平台有着较好的治疗效果。喷雾冷冻干燥制备AeDPI，可以结合喷雾干燥与冷冻干燥两者的优势，通过装备设计及工艺过程的优化，可以避免该技术的应用局限性。基于该原理，苏州大学开发了微流控喷雾冷冻干燥塔，应用于多种吸入粉雾剂研发的场景。最后，吴教授总结到，喷冷干有着类蒲公英结构AeDPI微粒，由此呈现出优异的空气动力学性能，该技术需要较多的基础研究。 DFE Pharma博士谢慧军 DFE Pharma博士谢慧军演讲了“生物药吸入递送工艺及辅料应用探讨”的主题报告。当前，从呼吸类药物市场数据分析来看，大分子吸入药物的研发管线数量在增加，市场销售额也有所上升，大分子吸入药物的应用前景未来可期。从生物类吸入药物的开发难点来看，主要存在化学不稳定和物理不稳定，对于生物大分子药物，需要通过如载体、递送装置、工艺及辅料等多方面因素的基础研究和优化来解决吸入制剂的成药性和稳定性。谢博士举例了海藻糖应用于单抗、甘露醇用于蛋白质/肽与其他赋形剂联合输送等辅料的应用，并总结了吸入给药在大分子生物药的给药应用上有哪些可选择的技术路线和合规路线。上海华瑞气雾剂有限公司董事长王振勇上海华瑞气雾剂有限公司董事长王振勇围绕“单/双剂量药物递送装置的开发与应用”的主题作了相关报告。他阐述了单剂量装置在鼻腔制剂中的应用方向，主要涉及癫痫、抑郁、偏头痛、阿托品过量、生物制剂等，目前市场上已有的品种有纳洛酮、地西泮、佐米曲普坦、胰高血糖素等。随后，他介绍了单剂量鼻喷装置的特点、结构、工作原理，装置可靠性和一致性评价，以及华瑞如何通过设计和流程控制达成单剂量鼻喷装置的可靠性和一致性，从而控制喷雾面积、喷射状态、喷射剂量、雾滴粒径分布。为了解决单剂量药物递送装置研发过程中的技术壁垒，华瑞做了一系列技术布局和解决方案，用以提升装配流程。上海上药信谊药厂有限公司药物研究所所长助理邵奇上海上药信谊药厂有限公司药物研究所所长助理邵奇分享了“新型抛射剂152a与1234的研究与应用”的主题报告。邵博士首先介绍了抛射剂替代研究的背景，目前药用气雾剂中含氟抛射剂主要有两类，即HFA-134a和HFA227ea。接着，他阐述了新一代抛射剂的理化性质、包装材料和制剂工艺、以及使用缺陷。对于抛射剂的变更，需要对其溶解性、包料、稳定性、以及防爆措施进行综合考量。从当前美国FDA现有的抛射剂应用数据来看，以HFA-152a和HFO-1234ze为抛射剂的产品分别已累计申请专利10余项，并有4项已在Clinical Trail 平台备案，而国内临床试验登记与信息公示平台暂无相关项目，较为空白。展望未来，他鼓励加快新产品开发以提升该领域的应用。优选口头报告讲者精彩花絮在优选口头报告环节，大会主办方邀请了三位优秀青年学者展示学术成果，聚焦吸入药物制剂领域，畅谈观点，共通才智，为吸入制剂产业发展储备新生力量，从而推进吸入药物技术创新发展和创新人才的交流。来自中国医学科学院北京协和医学院药用植物研究所的魏嘉兴，来自山东大学药学院的傅相蕾，以及来自中国医药工业研究总院药物临床研究中心的兰志龙，分别围绕“利用体外肺组织外植体模型增强对吸入药物肺亲和力的预测”、“可吸入脂质体递送奥希替尼和DNA治疗原位和转移性肺癌”、“吸入药物在成人肺局部药代动力学的临床研究评价要点”等主题进行了精彩演讲。东南大学教授佟振博本场专题论坛由东南大学教授佟振博主持。 END 如需获取更多数据洞察信息或公众号内容合作，请联系医药地理小助手微信号：pharmadl001

2024-04-02

·BioSpace

Bespak Confirms Completion of Inhaled and Nasal Drug Delivery Business Separation From Recipharm to Focus on the Transition to Low GWP pMDIs

Spin-out unites three sites to create a leading global CDMO as further significant investments announced at Holmes Chapel site HOLMES CHAPEL, UK / ACCESSWIRE / April 2, 2024 / Bespak today announced the completion of the transaction to separate Recipharm's former Advanced Delivery Systems Business Unit from the Recipharm Group to form a new standalone company. Both Bespak and Recipharm are backed by EQT Private Equity. The spin-out has created a leading global contract development and manufacturing organisation (CDMO) focused on drug-device combination products and drug delivery devices for pulmonary and nasal inhalation. Bespak confirms completion of inhaled and nasal drug delivery business separation from Recipharm. Historically, Bespak is the name used by its King's Lynn, UK site - a leading global supplier of pressurised Metered Dose Inhaler (pMDI) dosing valves and actuators and complex Dry Powder Inhaler (DPI) devices. The new Bespak Group consists of three sites and has a broader range of capabilities. Its early-stage laboratory in North Carolina, U.S., has over 20 years of experience in feasibility, analytical and product development services for inhaled and nasal drug products, while its Holmes Chapel, UK, site has a history in the scale-up and clinical and commercial supply of pMDIs and nasal drug-device combination products going back to the 1960s. Chris Hirst, formerly President of the Advanced Delivery Systems Business Unit at Recipharm, has been named CEO of the newly formed independent company, which will be headquartered at Holmes Chapel. "The spin-out of three former Recipharm sites, each with a long history in inhaled and nasal drug delivery, creates a new company with a clear vision and a unique offering for customers. The new Bespak will be the trusted innovation partner and sustainability leader in the transition to greener inhalers," Hirst said. Kåre Schultz, formerly CEO of Teva Pharmaceutical Industries, has been appointed Chairman of the Board of Directors of Bespak. Schultz headed Teva from 2017 to 2022 and has also served as Executive Vice President and COO at Novo Nordisk, CEO at Lundbeck, and Chairman of Royal Unibrew, a listed Danish brewery and beverage company. "I'm looking forward to working with the Board of Directors to help steer the new Bespak in its mission to help both patients and planet and to work in partnership with major global pharmaceutical companies to ensure continued patient access to life-saving medicines," commented Schultz. Bespak also announced a significant further investment in manufacturing capacity at its Holmes Chapel site, from which it manufactures a range of leading pMDIs for global pharmaceutical companies. The next stage of an extensive expansion plan has been implemented to enable the installation of commercial-scale and pilot-scale filling lines for the manufacture of pMDIs using HFA-152a, a propellant with a significantly lower Global Warming Potential (GWP) than currently used propellants. This commitment will enable Bespak to service the increasing demand from customers transitioning their inhaler portfolios to utilise a new generation of greener propellants. This announcement builds on the site's landmark milestone last year as it became the first CDMO to manufacture a pMDI at commercial scale with HFO-1234ze, a near-zero GWP propellant. The propellant was developed as a replacement for current hydrofluoroalkane (HFA) propellants that will be phased down, and eventually out, as a result of legislation designed to limit global warming. Chris Hirst added: "We are committed to leading the transition to low GWP propellants in pMDIs, and in making this investment we become the only CDMO - and indeed the only site - in the world to have the capability to manufacture at scale with both new green propellants: HFA-152a and HFO-1234ze. With our broad range of services and team of experts enabling us to develop and commercialise pMDIs, combined with our market-leading position in pMDI valves and actuators, our customers can be confident they are in safe hands as they make the transition to sustainable inhalers." Matthias Wittkowski, Partner within EQT Private Equity's Advisory Team, said: "The completion of the separation from Recipharm to form an independent company focussed on advancements in inhaled and nasal drug delivery - and particularly in the transition to greener pMDIs - creates a market leader in this specialised CDMO space. The creation of the new Bespak, combined with this significant investment in expanded manufacturing capability and capacity, provides a strong platform for growth and a unique opportunity to enable the industry to become more sustainable for the future. We are impressed by the experienced team led by Chris, and we look forward to supporting the new Bespak in its next phase of growth." Contact Information: Sarah Guinane Senior Content Lead, Notch Communications sarah.guinane@notchcommunications.co.uk SOURCE: Bespak View the original press release on newswire.com.

并购高管变更

2023-12-12

·BioSpace

Oz-UK Ltd announces new low-GWP manufacturing line installation to meet global need for pMDIs ahead of the Kigali Amendment deadline

Chippenham, UK, 6th December 2023: Oz-UK Ltd, the Chippenham-based contract research organization (CRO) dedicated to providing pressurized metered dose inhaler (pMDI) and liquid aerosol research and development (R&D), announces the installation of its new low-GWP (global warming potential) manufacturing line to meet global needs for pMDI investigation ahead of the Kigali Amendment deadline. The announcement – made at the Drug Delivery to the Lungs (DDL) conference in Edinburgh from 6-8 December 2023 – tackles head-on the pharmaceutical industry concern for phase-down of the use of fluorinated gases (F-gases) by 2047, stipulated by the Kigali Amendment. F-gas regulations have a significant impact on the market for inhalation products and switching to propellants with a lower GWP is a commercial imperative for pharmaceutical manufacturers. The new low-GWP line – funded in part by Oz-UK and in part by grants from Wiltshire Council through the UK Government’s Prosperity Funds – is located in one of Oz-UK’s two custom-built facilities in Chippenham, Wiltshire, and will be operational by July 2024. The new low-GWP line will add to the current client development services for low-GWP solution and suspension pMDI development programmes. The line will manufacture pMDIs containing HFO-1234ze and HFA-152a propellants and will allow 2.5 – 10-kilogram batches to be manufactured. As the pharmaceutical industry attempts to develop viable alternatives, these need to be trialled in new formulations and new devices to comply with the phase-down. Currently, R&D is focusing on moving away from the two most common HFA propellants, 134a and 227ea, and towards low-GWP HFA and HFO propellants, such as 152a and 1234ze, both of which the new Oz-UK manufacturing line is designed to accommodate. Low-GWP alternatives exhibit different physiochemical properties to their predecessors, which can impact the stability and spray formation associated with the formulation. Therefore, significant amount of R&D is needed to support the transition to next generation propellants for pMDIs. Oz-UK, which already offers formulation development services to the pharmaceutical, biotechnology and cannabinoid industries, is rapidly investing in its facilities to keep up with global demand for R&D, formulation and pilot production capabilities. Dr. David Lewis, Director of Oz-UK explains: “Development of inhalation products is limited by the difficulties of R&D in a pressurised environment and the propellant propulsion challenges of aerosol science. Our years of experience in this market mean that Oz-UK is uniquely positioned to support pharma at speed, with the facilities needed to undertake the R&D, formulation, and pilot testing of new pMDIs. We are already working on technical transfer and intellectual property (IP) transfer for a number of global businesses who have carried out this work with us, including Recipharm who also announced a collaboration with Oz-UK for its initiative to accelerate the development and manufacture of “green” pMDIs. The introduction of our new low-GWP line will enable more companies to undertake these projects more quickly as the deadline for F-gas phase-down approaches.” Oz-UK is rapidly investing in its existing facilities and development formulation services now include 10 litre mixing vessels and Pamasol suspension filling equipment. Uniquely, Oz-UK has both a schedule 1 & 2 Controlled Drugs Licence, enabling pMDI development work for a wide range of active pharmaceutical ingredients (APIs), within a regulated environment. Pharmaceutical and cannabinoid companies with R&D projects in aerosol propellant replacement, formulation design and IP submissions in inhalation are now able to manage the drug development project in a fully outsourced environment at Oz-UK before scale-up to manufacture in-house. For more information, please contact Oz-UK on info@oz-uk-labs.com. For further information: David Lewis – Oz-UK Ltd david.lewis@oz-uk-labs.com +44 (0) 795 795 6322 For media enquiries: Emma Perkin - Kapler Communications ozuk@kapleronline.com +44 (0) 1477 539545 Notes to editors The UK Shared Prosperity Fund (UKSPF) and Rural Prosperity Funds are part of the Government’s Levelling Up agenda, providing £2.6bn of funding for local investment across the UK from 2022 until March 2025. Wiltshire has been allocated £5.7m from UKSPF and a further £2.5m through the Rural Prosperity Funds. About Oz-UK Oz-UK is a UK-based CRO which aims to solve the challenges faced by inhalation product development in pharma and cannabis environments. Oz-UK offers clients formulation services, propellant replacement, bespoke formulation design for client pipelines and client IP submissions. Founded in 2017 and based in Chippenham, UK, Oz-UK provides a one-stop shop for pMDI technology from bench to product.

100 项与 1,1-二氟乙烷相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
哮喘	临床2期	英国	CHIESI Farmaceutici SpA	2022-08-03

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05472662 (CTgov)	临床2期	哮喘	25	Placebo 152a (Test)	蓋觸願製壓夢願觸顧範(網顧艱艱鏇夢壓願網憲) = 鏇襯夢淵餘憲齋襯齋醖選鏇觸鬱鹹築壓願製窪 (膚衊繭鹽壓夢築獵繭餘, 餘餘範糧積簾襯積網願 ~ 醖餘顧壓壓衊艱鏇鹹願) 更多	-	2024-10-15
				Placebo 134a (Reference)	蓋觸願製壓夢願觸顧範(網顧艱艱鏇夢壓願網憲) = 製壓醖鬱簾壓鏇築襯觸選鏇觸鬱鹹築壓願製窪 (膚衊繭鹽壓夢築獵繭餘, 獵醖夢醖構構願構繭製 ~ 積繭齋獵憲積構鹹鏇製) 更多